Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Voyager Therapeutics Inc
VYGR | US
4.32
USD-0.14
-3.03%
VYGR | US
Loading StockChartView...
About Voyager Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/03/2026
Close
4.32
Open
4.51
High
4.55
Low
4.29
Voyager Therapeutics Inc. a biotechnology company focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01 an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences Inc.; Pfizer Inc.; and Novartis Pharma A.G. for the research development and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics Inc. was incorporated in 2013 and is headquartered in Cambridge Massachusetts.
View LessVYGR | US
Risk
97.9
Sharpe
0.02
Luna's Score
51/100
Recommendation
Hold
Luna says (VYGR | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
124.4%1 month
97.9%3 months
69.9%6 months
66.4%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
29.89
Fwd. PE
-
Price to book
1.30
Debt to equity
0.14
Debt to assets
0.11
Ent. to EBITDA
2.59
Ent. to rev.
0.78
PEG
-
Other Fundamentals
EBITDA
-1.78M
MarketCap
235.58M
MarketCap(USD)
235.58M
Div. yield
-
Op. margin
-50.80
Erngs. growth
-
Rev. growth
509.50
Ret. on equity
3.38
Short ratio
6.27
Short perc.
6.54
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.71
Range1M
2.22
Range3M
2.22
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.82
Price X volume
3.13M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 2.59 | 0.53 | Expensive |
| Ent. to Revenue | 0.78 | 3,967.00 | Cheaper |
| PE Ratio | 29.89 | 41.03 | Cheaper |
| Price to Book | 1.30 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 69.86 | 72.80 | Par |
| Debt to Equity | 0.14 | -1.23 | Expensive |
| Debt to Assets | 0.11 | 0.25 | Cheaper |
| Market Cap | 235.58M | 3.66B | Emerging |
